Patient Organizations Urge Zero Co-Pay Policy To Lower Biosimilars Cost
Stakeholders Request HHS And CMS To Eliminate Out-Of-Pocket Costs For Medicare Part B
Executive Summary
A group of organizations representing patients, consumers, providers and taxpayers have extended support to the zero co-pay policy which would decrease significant barriers for prescribing lower-cost biosimilars. The stakeholders have urged the US HHS and CMS to reform Medicare payment policies, “which would allow patients better access to lower cost biosimilars.”
You may also be interested in...
Amgen Urges Balance In US Biosimilars Policy
Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.
AAM Calls For A Balance Instead Of Banning Pay-For-Delay
US President Joe Biden has signed an executive order asking the FTC to ban so-called “pay-for-delay” reverse-payment settlements. According to the order, this could help curb high prices that are in part the result of lack of competition among drug manufacturers. However, talking exclusively to Generics Bulletin, AAM senior vice president Jeff Francer insists on a balance, explaining that such settlements result in earlier access to biosimilars and generics.
Generics Coverage Worsens Under Medicare Plans In 2021
Based on the latest AAM-sponsored study by Avalere Health, the US off-patent industry association has asked policymakers to initiate Medicare Part D reforms. Generic prescription drugs are only placed on generic tiers 45% of the time in 2021, a significant decrease from the 64% seen in 2016.